Chief executive, Xbrane Biopharma
Appears in 1 story
Leading Xbrane into its first US launch, targeted for 2027
After four years and two FDA rejections, Xbrane Biopharma has US approval for its copy of Lucentis, one of the world's best-selling eye drugs. The regulator cleared Lucamzi (ranibizumab-blrz) two days before its own October 29 review deadline.
Updated 2 hours ago
No stories match your search
Try a different keyword
How would you like to describe your experience with the app today?
